PharmClass

The Ministry of Health’s Drug Advisory Committee has recommended:

• Galcanezumab 120 mg/mL solution for injection in pre-filled pen for prophylaxis of migraine in adults who have at least four migraine days a month prior to commencement of treatment with galcanezumab. Patients must have experienced an inadequate response, intolerance, or a contraindication to at least three migraine prophylactic medications. Treatment with galcanezumab should be stopped after 12 weeks if:
  a) in episodic migraine, the number of migraine days per month does not reduce by at least 50% compared with baseline;
  b) in chronic migraine, the number of migraine days per month does not reduce by at least 30% compared with baseline.

Funding status